Effects of fluoxetine and buspirone on the panicolytic-like response induced by the activation of 5-HT1A and 5-HT2A receptors in the rat dorsal periaqueductal gray

Psychopharmacology

Volumn 183, Issue 4, 2006, Pages 422-428

  De Bortoli, Valquíria Camin ^a   Nogueira, Regina Lúcia ^b,c   Zangrossi Jr , Hélio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b University Estácio de Sá   (Brazil)

^c UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

Author keywords

8 OH DPAT; DOI; Generalized anxiety; Panic disorder; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSPIRONE; FLUOXETINE; PIPERAZINE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ELECTRIC CURRENT; LONG TERM CARE; MALE; MICROINJECTION; NONHUMAN; PANIC; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; AMPHETAMINES; ANIMALS; ANTI-ANXIETY AGENTS; BUSPIRONE; FLUOXETINE; MALE; MICROINJECTIONS; PERIAQUEDUCTAL GRAY; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 28344440863     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0189-y     Document Type: Article

References (56)

1. Amano K, Tanikawa T, Iseki H, Kawabatake H, Notani M, Kawamura H, Kitamura K (1978) Single neuron analysis of the human midbrain tegmentum. Rostral mecencephalic reticulotomy for pain relief. Appl Neurophysiol 41:66-78
2. Andrade R, Nicoll RA (1987) Pharmacologically distinct actions of serotonin on single pyramidal neurones of the rat hippocampus recorded in vitro. J Physiol 394:99 124
3. Ballenger JC (1999) Selective serotonin reuptake inhibitors (SSRIs) in panic disorder. In: Nutt DJ, Ballenger JC, Lepine J-P (eds) Panic disorder. Clinical diagnosis, management and mechanisms. Martin Dunitz, London, pp 159-178
4. Bandler R, Shipley MT (1994) Columnar organization in the midbrain periaqueductal gray: modules for emotional expression? Trends Neurosci 17:379-389
5. Beck SG, Birnstiel S, Choi KC, Pouliot WA (1997) Fluoxetine selectively alters 5-hydroxytryptamine1A and gamma-aminobutyric acidB receptor-mediated hyperpolarization in area CA1, but not area CA3, hippocampal pyramidal cells. J Pharmacol Exp Ther 281:115-122
6. Beckett S, Marsden CA (1997) The effect of central and systemic injection of the 5-HT1A receptor agonist 8-OHDPAT and the 5-HT1A receptor antagonist WAY100635 on periaqueductal grey-induced defence behaviour. J Psychopharmacol 11:35-40
7. Beckett SR, Lawrence AJ, Marsden CA, Marshall PW (1992) Attenuation of chemically induced defence response by 5-HT1 receptor agonists administered into the periaqueductal gray. Psychopharmacology 108:110-114
8. Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220-226
9. Conn PJ, Sanders-Bush E (1987) Central serotonin receptors: effector systems, physiological roles and regulation. Psychopharmacology 92:267-277
10. Connor KM, Davidson JRT (1998) Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. Biol Psychiatry 44:1286-1294
11. Damjanoska KJ, Van de Kar LD, Kindel GH, Zhang Y, D'Souza DN, Garcia F, Battaglia G, Muma NA (2003) Chronic fluoxetine differentially affects 5-hydroxytryptamine (2A) receptor signaling in frontal cortex, oxytocin- and corticotropin-releasing factor-containing neurons in rat paraventricular nucleus. J Pharmacol Exp Ther 306:563-571
12. Deakin JFW, Graeff FG (1991) 5-HT and mechanisms of defense. J Psychopharmacol 5:305-315
13. den Boer JA, Slaap BR (1998) Review of current treatment in panic disorder. Int Clin Psychopharmacol 13 (suppl 4):S25-S30
14. De Vry J, Glaser T, Schuurman T, Schreiber R, Traber J (1991) 5-HT1A receptors in anxiety. In: Briley M, File SE (eds) New concepts in anxiety, Macmillan Press, London, pp 94-129
15. Elena Castro M, Diaz A, del Olmo E, Pazos A (2003) Chronic fluoxetine induces opposite changes in G protein coupling at pre and postsynaptic 5-HT1A receptors in rat brain. Neuropharmacology 44:93-101
16. Goa KL, Ward A (1986) Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 32:114-129
17. Graeff FG (1990) Brain defense systems and anxiety. In: Roth M, Burrows GD, Noyes R (eds) Handbook of anxiety. The neurobiology of anxiety. Elsevier, Amsterdam, pp 307-354
18. Graeff FG (2002) On serotonin and experimental anxiety. Psychopharmacology 163:467-476
19. Graeff FG (2004) Serotonin, the periaqueductal gray and panic. Neurosci Biobehav Rev 28:239-259
20. Graeff FG, Zangrossi H Jr (2002) Animal models of anxiety disorders. In: D'Haenen H, den Boer JA, Westenberg H, Willner P (eds) Textbook of biological psychiatry. Wiley, London, pp 879-893
21. Graeff FG, Silveira MC, Nogueira RL, Audi EA, Oliveira RM (1993) Role of the amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res 58:123-131
22. Graeff FG, Netto CF, Zangrossi H Jr (1998) The elevated T-maze as an experimental model of anxiety. Neurosci Biobehav Rev 23:237-246
23. Griffiths JL, Lovick TA (2002) Co-localization of 5-HT 2A-receptor- and GABA-immunoreactivity in neurones in the periaqueductal grey matter of the rat. Neurosci Lett 326:151-154
24. Invernizzi R, Bramante M, Samanin R (1994) Chronic treatment with citalopram facilitates the effect of a challenge dose on cortical serotonin output: role of presynaptic 5-HT1A receptors. Eur J Pharmacol 260:243-246
25. Jacob CA, Cabral AH, Almeida LP, Magierek V, Ramos PL, Zanoveli JM, Landeira-Fernandez J, Zangrossi H Jr, Nogueira RL (2002) Chronic imipramine enhances 5-HT(1A) and 5-HT (2) receptors-mediated inhibition of panic-like behavior in the rat dorsal periaqueductal gray. Pharmacol Biochem Behav 72:761-766
26. Jenck F, Moreau JL, Martin JR (1995) Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res 57:181-191
27. Jenck F, Moreau JL, Berendsen HH, Boes M, Broekkamp CL, Martin JR, Wichmann J, Van Delft AM (1998) Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol 8:161-168
28. Kiser RS, Lebovitz RM (1975) Monoaminergic mechanisms in aversive brain stimulation. Physiol Behav 15:47-53
29. Kiser RS, German DC, Lebovitz RM (1978) Serotonergic reduction of dorsal central gray area stimulation-produced aversion. Pharmacol Biochem Behav 9:27-31
30. Klein DF, Fink M (1962) Psychiatric reaction patterns to imipramine. Am J Psychiatry 119:432-438
31. Lepola U, Arato M, Zhu Y, Austin C (2003) Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry 64:654-662
32. Li Q, Muma NA, van de Kar LD (1996) Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist. J Pharmacol Exp Ther 279:1035-1042
33. Lovick TA (2000) Panic disorder - a malfunction of multiple transmitter control systems within the midbrain periaqueductal gray matter. Neuroscientist 6:48-59
34. Lydiard RB, Ballenger JC (1987) Antidepressants in panic disorder and agoraphobia. J Affect Disord 13:153-168
35. Marseillan RF (1977) A solid state sine-wave stimulator. Physiol Behav 19:339-340
36. Mongeau R, Marsden CA (1997) Effect of imipramine treatments on the 5-HT1A-receptor-mediated inhibition of panic-like behaviours in rats. Psychopharmacology 131:321-328
37. Nashold BS Jr, Wilson WP, Slaughter DG (1969) Sensations evoked by stimulation in the midbrain of man. J Neurosurg 30:14-24
38. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, Fava M (2000) Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 157:1423-1428
39. Nogueira RL, Graeff FG (1995) Role of 5-HT receptor subtypes in the modulation of dorsal periaqueductal gray generated aversion. Pharmacol Biochem Behav 52:1-6
40. Olds ME, Olds J (1962) Approach - escape interactions in rat brain. Am J Physiol 203:803-810
41. Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates, 3rd edn. Academic Press, San Diego
42. Pecknold JC (1997) A risk-benefit assessment of buspirone in the treatment of anxiety disorders. Drug Saf 16:118-132
43. Poltronieri SC, Zangrossi H Jr, de Barros Viana M (2003) Antipanic-like effect of serotonin reuptake inhibitors in the elevated T-maze. Behav Brain Res 147:185-192
44. Raap DK, Evans S, Garcia F, Li Q, Muma NA, Wolf WA, Battaglia G, Van De Kar LD (1999) Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins. J Pharmacol Exp Ther 288:98-106
45. Schenberg LC, Graeff FG (1978) Role of the periaqueductal gray substance in the antianxiety action of benzodiazepines. Pharmacol Biochem Behav 9:287-295
46. Schenberg LC, Bittencourt AS, Sudre EC, Vargas LC (2001) Modeling panic attacks. Neurosci Biobehav Rev 25:647-659
47. Schneier FR, Liebowitz MR, Davies SO, Fairbanks J, Hollander E, Campeas R, Klein DF (1990) Fluoxetine in panic disorder. J Clin Psychopharmacol 10:119-121
48. Schütz MT, de Aguiar JC, Graeff FG (1985) Anti-aversive role of serotonin in the dorsal periaqueductal grey matter. Psychopharmacology 85:340-345
49. Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E (1993) The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 88:1-11
50. Shen C, Li H, Meller E (2002) Repeated treatment with antidepressants differentially alters 5-HT1A agonist-stimulated [35S]GTP gamma S binding in rat brain regions. Neuropharmacology 42:1031-1038
51. Siemiatkowski M, Sienkiewicz-Jarosz H, Czlonkowska AI, Bidzinski A, Plaznik A (2000) Effects of buspirone, diazepam, and zolpidem on open field behavior, and brain [3H] muscimol binding after buspirone pretreatment. Pharmacol Biochem Behav 66:645-651
52. Sprouse JS, Aghajanian GK (1987) Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse 1:3-9
53. Teixeira RC, Zangrossi H Jr, Graeff FG (2000) Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety. Pharmacol Biochem Behav 65:571-576
54. Treit D, Fundytus M (1988) A comparison of buspirone and chlordiazepoxide in the shock-probe/burying test for anxiolytics. Pharmacol Biochem Behav 30:1071-1075
55. Vargas LC, Schenberg LC (2001) Long-term effects of clomipramine and fluoxetine on dorsal periaqueductal grey-evoked innate defensive behaviours of the rat. Psychopharmacology 155:260-268
56. Zanoveli JM, Nogueira RL, Zangrossi H Jr (2005) Chronic imipramine treatment sensitizes 5-HT1A and 5-HT2A receptors in the dorsal periaqueductal gray matter: evidence from the elevated T-maze test of anxiety. Behav Pharmacol (in press)